|
Research on Streptococcus agalactiae disease in tilapia: a review
SU You-lu, LIU Chan, DENG Yi-qin, GUO Zhi-xun, FENG Juan
Journal of Dalian Ocean University
2019, 34 (5):
757-.
DOI: 10.16535/j.cnki.dlhyxb.2018-231
Streptococcus
agalactiae
as one pathogen in tilapia has brought huge economic losses to the tilapia breeding industry due to strong contagiousness and high mortality by the pathogen. This pathogen infects tilapia by different pathways, including cohabitation, oral route, immersion, intraperitoneal and intramuscular inoculation, and is capable of replicating in tilapia bloodstream, penetrating the blood-brain barrier into brain, resulting in meningitis, and passing through the mucus layer of both the stomach and intestine and finally adhered, colonized and invaded the gastrointestinal epithelium, leading to typical histopathological changes, including meningitis, epicarditis, hemorrhage in renal interstitium, multifocal necrotizing splenitis and septicemia in tilapia. The most frequent clinical symptoms of affected tilapia are erratic swimming, exophthalmia, hemorrhage at the operculum, pectoral, and ventral areas and rapidly progressing mortality. Traditional diagnosis methods for the detection of
S
.
agalactiae
in the host tissues are based on bacterial culture, and DNA-based methods including PCR and loop-mediated isothermal amplification are increasingly used. Molecular typing of
S
.
agalactiae
strains has been performed by different methods, such as molecular serotyping, amplified fragment length polymorphism, multiple-locus variant-repeat assay, and pulsed field gel electrophoresis, multilocus sequence typing. Virulence genes have faster mutation rates and higher polymorphism than housekeeping genes, and the multi-virulence locus sequencing typing method can be widely used to evaluate genetic variation in
S
.
agalactiae
. At present, aquaculture depends on antibiotics to treat or prevent
S
.
agalactiae
disease in tilapia. Although these antimicrobials have some benefits, the abuse of antibiotics occurs during tilapia production, leading to the development of antimicrobial-resistant strains. Although vaccination is an alternative method to control streptococcal diseases, few commercial vaccines are currently available for treatment of
S
.
agalactiae
disease in a large scale tilapia production. This paper comprehensively summarizes the latest research progress and development trends in etiology, epidemiology, pathology, pathogenic mechanism, detection methods, molecular typing, antibiotic resistance and vaccines of
S
.
agalactiae
in tilapia. The current problems that need to be solved are discussed and valuable measurements are suggested for the prevention and control of
S
.
agalactiae
disease in tilapia.
Related Articles |
Metrics
|
|